Clinical Trial Update: A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for QL1706 plus lenvatinib in advanced renal cell carcinoma (Phase 1/2) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Advanced Renal Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN